2016 American Society for Clinical Oncology (ASCO) Presentation
June 6, 2016: The Weill Cornell Medicine team presented data at the 2016 American Society for Clinical Oncology (ASCO) annual meeting about a new technology to accurately and cost-effectively identify high risk myeloma. Matching the level of disease aggressiveness with specific treatments is tied to better outcomes. Learn more about this new tool and what this means for myeloma patients.
Myeloma Center Awarded Prestigious LLS Translational Research Grant
The Myeloma Center in collaboration with Weill Cornell's Monical Guzman, PhD have received a prestigious translational research grant from the Leukemia and Lymphoma Society (LLS) to study the genesis of secondary malignancies in Multiple Myeloma.
Multiple Myeloma is characterized by the uncontrolled proliferation of malignant plasma cells. The introduction of novel agents has resulted in improvement in survival. However, long term use of these agents may lead to the development of second primary malignancies (SPM).
The grant will allow the researchers to examine factors that contribute to the development of secondary malignancies and identify early changes that could be used as predictors of the risk for SPMs."